

August 28, 2013

Nissan Chemical Industries, Ltd.

To whom it may concern:

Announcement Regarding a Pharmaceutical (Notice)

We hereby announce that we published the following notice in the “Nikkan Yakugyo” and the “Yakuji Nippo” today.

Notice : “Patent Rights Relevant to Pitavastatin Calcium”

Notice

Patent Rights Relevant to Pitavastatin Calcium

Pitavastatin calcium is a pharmaceutical whose active ingredient is manufactured by Nissan Chemical Industries, Ltd. (hereinafter referred to as “Nissan Chemical”), and which is manufactured and sold by Kowa Company, Ltd. (hereinafter referred to as “Kowa”) under the brand names “Livalo Tablet 1 mg,” “Livalo Tablet 2 mg,” “Livalo Tablet 4 mg,” “Livalo OD Tablet 1 mg,” and “Livalo OD Tablet 2 mg,” and sold by Kowa Pharmaceutical Co., Ltd.

With regard to pharmaceuticals containing pitavastatin calcium as an active ingredient, patent rights relevant to the crystal form of the active ingredient (Japanese Patent No. 5,186,108, Japanese Patent No. 5,192,147, and Japanese Patent No. 5,267,643), patent rights relevant to the method of manufacturing the active ingredient (Japanese Patent No. 4,433,156, Japanese Patent No. 4,281,248, and Japanese Patent No. 4,496,586), both owned by Nissan Chemical, patent rights relevant to pharmaceutical formulations (Japanese Patent No. 3,276,962, and Japanese Patent No. 5,166,876), co-owned by Kowa and Nissan Chemical, and patent rights relevant to pharmaceutical formulations (Japanese Patent No. 4,981,194, Japanese Patent No. 5,190,159, and Japanese Patent No. 5,259,880), owned by Kowa are valid and remain in force.

In manufacturing, importing or selling the pharmaceuticals containing pitavastatin calcium as an active ingredient, there is a risk of infringing the intellectual property rights of Kowa and Nissan Chemical, including the patent rights specified above.

Kowa and Nissan Chemical intend to take strict and immediate legal action against any activity that infringes or may infringe the intellectual property rights owned by Kowa and Nissan Chemical, including the patent rights specified above.

Kowa and Nissan Chemical courteously request that any company which recently received marketing approval of pitavastatin calcium pay full attention to the intellectual property rights of Kowa and Nissan Chemical, and surely refrain from conducting any activity that infringes any such intellectual property rights.

August 28, 2013

Kowa Company, Ltd.

6-29, Nishiki 3-chome, Naka-ku, Nagoya City, Aichi Prefecture, Japan

Nissan Chemical Industries, Ltd.

7-1, Kanda Nishiki-cho 3-chome, Chiyoda-ku, Tokyo, Japan